Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jan 22:2021:8864522.
doi: 10.1155/2021/8864522. eCollection 2021.

Comparative Evaluation of the Treatment of COVID-19 with Multicriteria Decision-Making Techniques

Affiliations
Comparative Study

Comparative Evaluation of the Treatment of COVID-19 with Multicriteria Decision-Making Techniques

Figen Sarigul Yildirim et al. J Healthc Eng. .

Abstract

Objectives: The outbreak of coronavirus disease 2019 (COVID-19) was first reported in December 2019. Until now, many drugs and methods have been used in the treatment of the disease. However, no effective treatment option has been found and only case-based successes have been achieved so far. This study aims to evaluate COVID-19 treatment options using multicriteria decision-making (MCDM) techniques.

Methods: In this study, we evaluated the available COVID-19 treatment options by MCDM techniques, namely, fuzzy PROMETHEE and VIKOR. These techniques are based on the evaluation and comparison of complex and multiple criteria to evaluate the most appropriate alternative. We evaluated current treatment options including favipiravir (FPV), lopinavir/ritonavir, hydroxychloroquine, interleukin-1 blocker, intravenous immunoglobulin (IVIG), and plasma exchange. The criteria used for the analysis include side effects, method of administration of the drug, cost, turnover of plasma, level of fever, age, pregnancy, and kidney function.

Results: The results showed that plasma exchange was the most preferred alternative, followed by FPV and IVIG, while hydroxychloroquine was the least favorable one. New alternatives could be considered once they are available, and weights could be assigned based on the opinions of the decision-makers (physicians/clinicians). The treatment methods that we evaluated with MCDM methods will be beneficial for both healthcare users and to rapidly end the global pandemic. The proposed method is applicable for analyzing the alternatives to the selection problem with quantitative and qualitative data. In addition, it allows the decision-maker to define the problem simply under uncertainty.

Conclusions: Fuzzy PROMETHEE and VIKOR techniques are applied in aiding decision-makers in choosing the right treatment technique for the management of COVID-19.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Positive and negative aspects of each COVID-19 treatment option. The higher the criterion stands in the graph in the positive side, the higher it contributes to the positive side of the technique. Similarly, the lower the criterion stands in the graph on the negative side, the higher it contributes to the negative side of the technique.

References

    1. World Health Organization. Situation updates on March 26, 2020. 2020. https://covid19.who.int/
    1. Rothe C., Schunk M., Sothmann P., et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New England Journal of Medicine. 2020;382(10):970–971. doi: 10.1056/nejmc2001468. - DOI - PMC - PubMed
    1. Kupferschmidt K. Study claiming new coronavirus can be transmitted by people without symptoms was flawed science. The Journal of Infectious Diseases. 2020;3
    1. Bai Y., Yao L., Wei T., et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):p. 1406. doi: 10.1001/jama.2020.2565. - DOI - PMC - PubMed
    1. Li Q., Guan X., Wu P., et al. Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia. New England Journal of Medicine. 2020;382(13):1199–1207. doi: 10.1056/NEJMoa2001316. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources